@misc{10481/80413,
year = {2022},
month = {6},
url = {https://hdl.handle.net/10481/80413},
abstract = {PURPOSE Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal
cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown.
METHODS We constructed an OPC risk prediction model that integrates (1) relative odds of OPC for HPV16-E6
serostatus and cigarette smoking from the human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2)
US population risk factor data from the National Health Interview Survey, and (3) US sex-specific population
rates of OPC and mortality.
RESULTS The nine HPVC3 cohorts included 365 participants with OPC with up to 10 years between blood draw
and diagnosis and 5,794 controls. The estimated 10-year OPC risk for HPV16-E6 seropositive males at age
50 years was 17.4% (95% CI, 12.4 to 28.6) and at age 60 years was 27.1% (95% CI, 19.2 to 45.4). Corresponding
5-year risk estimates were 7.3% and 14.4%, respectively. For HPV16-E6 seropositive females, 10-
year risk estimates were 3.6% (95% CI, 2.5 to 5.9) at age 50 years and 5.5% (95% CI, 3.8 to 9.2) at age 60 years
and 5-year risk estimates were 1.5% and 2.7%, respectively. Over 30 years, after a seropositive result at age
50 years, an estimated 49.9% of males and 13.3% of females would develop OPC. By contrast, 10-year risks
among HPV16-E6 seronegative people were very low, ranging from 0.01% to 0.25% depending on age, sex, and
smoking status.
CONCLUSION We estimate that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC,
with 10-year risks of 17%-27% for males and 4%-6% for females age 50-60 years in the United States. This high
level of risk may warrant periodic, minimally invasive surveillance after a positive HPV16-E6 serology test,
particularly for males in high-incidence regions. However, an appropriate clinical protocol for surveillance
remains to be established.},
organization = {United States Department of Health & Human Services
National Institutes of Health (NIH) - USA
NIH National Cancer Institute (NCI)	5U01CA195603-02
U01CA202979},
organization = {Division of Cancer Epidemiology and Genetics, US NCI},
organization = {VicHealth},
organization = {Canadian Institutes of Health Research (CIHR)},
organization = {Cancer Council Victoria},
organization = {National Health and Medical Research Council (NHMRC) of Australia	209057
396414
1074383},
organization = {National Cancer Institute P30	CA016056},
organization = {Einstein Cancer Research Center	CA013330},
organization = {United States Department of Health & Human Services},
organization = {National Institutes of Health (NIH) - USA},
organization = {NIH National Heart Lung & Blood Institute (NHLBI)	75N92021D00001
75N92021D00002
75N92021D00003
75N92021D00004
75N92021D00005},
publisher = {Lippincot Williams & Wilkins},
title = {Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium},
doi = {10.1200/JCO.21.01785},
author = {Robbins, Hilary A. and Sánchez Pérez, María José},
}